Accès à distance ? S'identifier sur le proxy UCLouvain
Improvement in das28 response through 1-yr of golimumab treatment in pts with active RA despite treatment with MTX: A randomized, double blind, placebo-controlled, dose-ranging trial
Primary tabs
| Document type | Communication à un colloque (Conference Paper) – Abstract, Présentation orale avec comité de sélection |
|---|---|
| Publication date | 2008 |
| Language | Anglais |
| Conference | "Annual Meeting of the British-Society-Rheumatology/Spring Meeting of British Health Professional in Rheumatology", Liverpool (England) (Apr 22-25, 2007) |
| Journal information | "Rheumatology" - Vol. 47, p. II50-II51 (2008) |
| Peer reviewed | yes |
| issn | 1462-0324 |
| e-issn | 1462-0332 |
| Publisher | Oxford Univ Press (Oxford) |
| Affiliations |
UCL
- Cliniques universitaires Saint-Luc UCL - MD/MINT - Département de médecine interne |
| Links |
| Bibliographic reference | Dasgupta, B. ; Durez, Patrick ; Kay, J. ; Matteson, E. L. ; Nash, P. ; et. al. Improvement in das28 response through 1-yr of golimumab treatment in pts with active RA despite treatment with MTX: A randomized, double blind, placebo-controlled, dose-ranging trial.Annual Meeting of the British-Society-Rheumatology/Spring Meeting of British Health Professional in Rheumatology (Liverpool (England), Apr 22-25, 2007). In: Rheumatology, Vol. 47, p. II50-II51 (2008) |
|---|---|
| Permanent URL | http://hdl.handle.net/2078.1/59285 |